President Donald Trump surprised pharma CEOs on Thursday with letters demanding they acquiesce to his most-favored drug-pricing scheme (see what we did there?) by the end of September, setting up a late-summer lobbying fight for the industry.

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.